Laura is a health economist by background and holds a MSc in international healthcare management, economics and policy from Bocconi University in Milan.
She has worked in PMA consulting for the past 12 years across different companies: she started her career in IMS in Milan, then moved to Simon-Kucher in Bonn, Milan and Boston to land in London in 2012 working for GfK Bridgehead prior joining PAREXEL, where she spent the last 4 years working as a Director in the Pricing and Market Access department. During her consulting career Laura has worked on strategic projects across varied therapeutic areas and all stages of drugs’ life cycle, in particular: pricing and reimbursement strategy and launching sequence; market access strategy, including advisory boards and mock negotiation workshops; value proposition development and payer testing; innovative contracting strategies; evaluation and prioritization of indication expansion opportunities for existing and pipeline products.
In her free time, Laura loves to go running, cooking, traveling and reading, but most of all she loves spending time with her 2 year old boy Sami. Laura is Italian by origin and speaks Italian, English and Spanish.
“Three Drug Development Habits to Mitigate Commercial Risk”, HBR, 2016
“Price Globally, Negotiate Locally”, HBR, 2015
“Cross-Markets Variability of Innovation Benefit’s Evaluations: How Italy Compares to France, Germany and the United States”, Value in Health, Volume 16, Issue 7, Page A482, ISPOR 2013
- Life Sciences
Market Access / Pricing / MEAs / Orphan Drugs and EAPs
- Life Sciences
MSc, Healthcare Management, Economic and Policy, Bocconi University
BA, International Institutions and Public Administration Management, Bocconi University